TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01964508

Intervention type: OTHER
Intervention: Fine needle aspiration
Study: NCT01848015

Intervention type: OTHER
Intervention: detection of CTCs
Study: NCT03161535

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and dietary education
Description: 1. A 12-week regimen of home-based walking exercises, comprising walking at a moderate intensity for 40 min, three times a week, was administered along with weekly exercise counseling. After collecting pretrial measurements, we explained the participants how to perform the exercises, according to an instruction manual for the exercise regimen. The detailed instructions, provided at the hospital clinics, included the determination of activity intensity, demonstration of pulse measurement, criteria for scores of 6-20 on the Borg's rating of perceived exertion (RPE), prevention of exercise-related injuries, and conditions necessitating termination of an exercise session. Participants were instructed that the exercises would be effective only if they reached 60%-80% of the target heart rate, as determined by the Karvonen method, and 13-15 on the RPE.~2. Diet-teaching program (using dietary education booklet).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weekly telephone consultations concerning exercise and diet.
Description: For each participant, we discussed exercise regimen-related issues and diet weekly through the telephone. For instance, we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects.
Study: NCT04564417

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: W0180
Description: Participants will receive W0180 in a 21-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: W0180
Description: Participants will receive W0180 in a 21-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: W0180
Description: Participants will receive W0180 in a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive Pembrolizumab 200 mg flat dose as IV infusion every three weeks (Q3W) in a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive Pembrolizumab 200 mg flat dose as IV infusion every three weeks (Q3W) in a 21-day cycle.
Study: NCT02513563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will be treated with carboplatin (area under the curve 5 (AUC5) will be used to determine the dosage) twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants will be treated with paclitaxel 175 mg/m\^2 twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: Participants will receive AZD1775 225 mg twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
Study: NCT03166917

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D printing implant
Description: 3D printing implants in bone defect

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: autogenous bone grafting
Description: 3D printing implants in bone defect
Study: NCT03104881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D exoskeleton type robot
Description: 3 dimension exoskeleton type upper extremity robot

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2D end-effector type robot
Description: 2 dimension end-effector type upper extremity robot
Study: NCT00976807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Eight week programme of twice-weekly (sixteen sessions) supervised exercise and education sessions. Exercise will include aerobic cardiovascular and upper and lower limb strengthening exercises. Each session will comprise a warm-up period, followed by individualised exercises, and completed with a cool-down, and last approximately 40minutes.~Aerobic exercise will be prescribed based on the results of walking tests and include walking, step-ups, cycling, and strength prescription according to the repetition maximum principle. Patients will complete three sets using this weight.~Furthermore Borg scores will be used within each session to guide and direct exercise intensity. A home exercise programme will also be designed and accompanied by a manual detailing the individual warm-up, exercises and cool-down, and diary sections to record independent activity.~Each session will also include an education session where relevant.
Study: NCT04828421

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus and Bifidobacterium lactis
Description: Probiotics

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01969708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aflibercept

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Study: NCT01075243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Description: Paracetamol 1000mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 650 mg
Description: Paracetamol 650 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01762410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P7170
Description: Patients will receive study drug on a daily basis for twenty-one days according to the dose and schedule specified for a particular cohort of therapy. This 21 day administration will define a treatment cycle. Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, death or withdrawal from the protocol as specified.
Study: NCT00691613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alpha
Description: The dosage (60.000 I/U Epoetin alpha) will be diluted in 10 ml of 0.9% sodium chloride solution and injected in a single dose intravenously in the dominant forearm (the non-dominant forearm will be used as ischemic model).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: 0.9% sodium chloride solution as placebo dosage is 10 ml, which will be administered in the same manner as the interventional medicinal product.
Study: NCT01591200

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Mesenchymal Stem Cells
Description: High dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Mesenchymal Stem Cells
Description: Intermediate dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Mesenchymal Stem Cells
Description: Low dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
Study: NCT02553213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy
Description: The surgical procedure and aftercare is indicated and performed according to the routine clinical setting of the Hospital. Patients stay 5 days stationary after surgical treatment. They receive a defined easy digestible diet, starting with liquid and mash food.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass
Description: The surgical procedure and aftercare is indicated and performed according to the routine clinical setting of the Hospital. Patients stay 5 days stationary after surgical treatment. They receive a defined easy digestible diet, starting with liquid and mash food.

Intervention type: OTHER
Group type: OTHER
Intervention: Caloric restriction diet
Description: Patients of the control group do not undergo surgical treatment. They undergo a caloric restriction diet for 5 days. This diet is adapted to the postoperative diet of the patients included in the two other groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: easy digestible diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: easy digestible diet
Study: NCT00788216

Intervention type: OTHER
Intervention: Discussion & scoring of health states related to the treatment of cervical cancer
Description: Subjects will be interviewed using the visual analog score and time trade off methods.

Intervention type: OTHER
Intervention: Discussion & scoring of health states related to the treatment of cervical cancer
Description: Subjects will be interviewed using the visual analog score and time trade off methods.
Study: NCT02923973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound cervical length screening
Description: Serial transvaginal ultrasound cervical length scan every week from 16 to 24 weeks
Study: NCT01171859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline + Tauroursodeoxycholic acid
Description: doxycycline 100 mg twice a day for 12 months; tauroursodeoxycholic acid 250 mg three times a day for 12 months
Study: NCT02028806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
Study: NCT01849510

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated 12x3 Gy + integrated boost 12x4 Gy
Description: hypofractionated, homogeneous radiation (12x3 Gy) with simultaneously administrated, integrated boost (12x4 Gy) mediated by IGRT \& hfSRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: hypofractionated 10x3 Gy
Description: hypofractionated, homogeneous radiation (10x3 Gy)
Study: NCT04757506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: opioid receptor antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04299373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol: Oral administration
Description: Patients who plan to undergo bariatric surgery will consume a controlled dose of alcohol orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol: Intravenous administration
Description: Patients who plan to undergo bariatric surgery will be infused with alcohol intravenously.
Study: NCT00566436

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote endarterectomy of the superficial femoral artery
Description: Exposure of the common femoral, superficial femoral and profunda femoral artery through a single groin incision. Arteriotomy in the proximal SFA followed by dissection of the intima core beyond the occluded segment using the Vollmar ringstripper. The ringstripper is exchanged for a Mollring cutter all under fluoroscopic guidance. With the Mollring Cutter transection of intima core is carried out, remote from the site of entry. After removal of the intima core the transection zone is secured with an aSpire stent after balloon angioplasty. A completion arteriography will verify a patent artery, and embolectomy can be performed when necessary. As indicated a common femoral artery and profundaplasty can be performed and the arteriotomy may be closed with or without patch.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprageniculate femoropopliteal bypass
Description: Groin and suprageniculate incision, venous (Saphenous vein) or PTFE graft with end to side anastomoses. If the saphenous vein is truly applicable for grafting will ultimately be an intra-operative decision (despite pre-operative venous mapping)
Study: NCT01091064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Randomization early depart
Description: Patients will be randomized to either an early depart or for being seen by a physician.
Study: NCT01169103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Description: Initial rhGH dose 0.4mg administered by subcutaneous injection daily. Dose will be increased to 0.6 mg after one week and then increased to 0.8mg after two weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by daily subcutaneous injections. Sham increases will be used.
Study: NCT02468817

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Exercise
Description: 2 (two) 1-hour of vigorous exercise bouts under different thermal conditions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnitude of Ca loss during Exercise at 26 degrees Celcius
Description: Blood samples at 15-min intervals starting 15 min before exercise and ending 60 min after exercise
Study: NCT01271777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFT505 80mg
Description: hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: hard gelatin capsules, oral administration, 4 capsules per day before breakfast
Study: NCT03309020

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Cataract surgery and aqueous humor sampling.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Cataract surgery and aqueous humor sampling.
Study: NCT04002401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered according to package insert
Study: NCT04642872

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant BIT
Description: Not use of unaffected hand containment. Both hand are use to improve the bimanual coordination

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant BIT
Description: Not use of unaffected hand containment. Both hand are use to improve the bimanual coordination

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant BIT
Description: Not use of unaffected hand containment. Both hand are use to improve the bimanual coordination
Study: NCT03983733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: To carry out an interventional dietary study using standardised meals to predict an individual's metabolic response to certain foods, using their gut microbiome, metabolic profile, and other measurable characteristics such as weight, sleep and exercise.
Study: NCT03454295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Participants will be asked to reflect on their caregiving experience and specifically, when the receipt of a supportive intervention that addresses existential distress would have been most appropriate and well received.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning-Centered Psychotherapy for Cancer Caregivers / MCP-C
Description: MCP-C is structured as a 7-session (1-hour weekly or biweekly sessions) individual intervention that utilizes a mixture of didactics, discussion and experiential exercises that focus around particular themes related to meaning and cancer caregiving

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care / EUC
Description: The enhancement to usual care in this study involves the inclusion of screening and targeted referral components as suggested by Reynolds et al. \[79\]. Research study assistants conducting the screening and providing feedback and referrals will be trained in the NCCN guidelines for distress management and will discuss the screening results and associated recommendations with the study PI (NCCN) \[63\]. As of November, 2017, ICs of patients seen in the Neurology Service at MSKCC are not consistently screened for distress and offered targeted referrals. Participants randomized to EUC will receive feedback about their level of distress (based on the Distress Thermometer administered at screening) after randomization. Within a week of randomization, and post-baseline, the study RSA will send EUC participants appropriate targeted referrals based on levels of distress and problem areas endorsed.
Study: NCT01931540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Three times a week, for four months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Three times a week, for four months.
Study: NCT06156020

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic endonasal surgery
Description: Endoscopic endonasal transsphenoidal approach for resection of pituitary adenomas
Study: NCT00517296

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUA with seton placement if necessary
Description: Patients randomized to the combination therapy group, the surgeon will have access to EUS findings.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUA with seton placement if necessary
Description: Patients randomized to the combination therapy group, the surgeon will have access to EUS findings.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: Patients began therapy with adalimumab using clinic standards for dosing.
Study: NCT04642872

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant CIMT/BIT
Description: Use unaffected hand containment in part of the intervention and then, both hands in bimanual activities without containment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant CIMT/BIT
Description: Use unaffected hand containment in part of the intervention and then, both hands in bimanual activities without containment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant CIMT/BIT
Description: Use unaffected hand containment in part of the intervention and then, both hands in bimanual activities without containment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Following the usual therapy in the baby.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Following the usual therapy in the baby.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: Following the usual therapy in the baby.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: infant cimt
Description: use of unaffected hand containment to improve the use of affected hand with unimanual activities

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: infant cimt
Description: use of unaffected hand containment to improve the use of affected hand with unimanual activities

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: infant cimt
Description: use of unaffected hand containment to improve the use of affected hand with unimanual activities
Study: NCT02711969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib mesylate
Description: 1,000mg Apatinib mesylate p.o. qd
Study: NCT03373201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study: NCT01675479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LASIK correction of hyperopic refractive errors
Description: Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System
Study: NCT02706132

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells(MSCs)
Description: Six doses of 1\*10\^6/kg body weight MSCs are given, intravenously.
Study: NCT02638480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KneeMD
Description: KneeMD is a subject-controlled knee rehabilita¬tion device that helps subjects who have undergone total knee replacements or other major knee surger¬ies improve range of motion and stretch in extension.
Study: NCT00106418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: 13 mg/m2 of romidepsin intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
Study: NCT00408252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biopsies
Description: No intervention, only biopsy for translational project

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: no intervention
Study: NCT02939612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App for stress management
Description: An app consisting of 10 modules that teaches stress management, cognitive behavioral coping skills and relaxation training.
Study: NCT02174042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tangning Tongluo Capsule
Description: Taken drugs 3 times a day, with each time 3 grains
Study: NCT03567434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol vs. Placebo
Description: Using a randomized, cross-over design, all subjects will consume evening alcohol (and a fluid-control placebo) in a dose that mimics binge drinking.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol vs. Placebo
Description: Using a randomized, cross-over design, all subjects will consume evening alcohol (and a fluid-control placebo) in a dose that mimics binge drinking.
Study: NCT03933904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus (also known as rapamycin) inhibits the mTOR protein kinase and is approved by the USA FDA for the prevention of allograft rejection in renal transplant patients ≥ 13 years of age and for the treatment of lymphangioleiomyomatosis.